Navigation Links
FDA Formally Accepts Dune Medical's MarginProbe™ System Pre-Market Approval (PMA) Application and Grants Expedited Review Status
Date:5/16/2011

FRAMINGHAM, Mass., May 16, 2011 /PRNewswire/ -- Dune Medical Devices, Inc. today announced that the U.S. Food and Drug Administration (FDA) formally accepted for filing the company's Pre-Market Approval (PMA) application for the MarginProbe™ System.  The FDA's actions mean that the PMA application was sufficiently complete and ready for substantive review.  Additionally, the FDA believes MarginProbe represents a breakthrough technology that may offer a clinically meaningful advantage, and, since there is no legally marketed alternative device, confirmed that the PMA application has been granted expedited review.

"We're extremely pleased that the FDA has accepted the MarginProbe System PMA application and granted expedited review," said Dune Medical CEO Bill Densel.  "Our mission is to develop a range of applications that allow physicians to detect cancer in targeted tissue in real time, and react immediately.  This milestone with MarginProbe brings us one step closer to providing surgeons with an intraoperative technology that detects microscopically positive margins in patients undergoing surgery for breast cancer."

The PMA submission includes data from the pivotal study recently presented Friday, April 29 at the 12th Annual Meeting of the American Society of Breast Surgeons (ASBS) in Washington, DC.

Successful breast conserving surgery requires cancer-free margins at the edges of excised tissue.  However, real time, intraoperative methods currently available to surgeons are limited in their ability to identify microscopically-positive margins.  Because of this, patients frequently require re-excision procedures, which are reported to take place in up to 30 percent of patients.  Readmissions for re-excision to obtain clear margins have been shown to increase cost and emotional distress for patients, as well as have the potential for more scarring and deformation at the surgical site.  

About the MarginProbe™ System

The MarginProbe System provides real time, intraoperative detection of cancerous tissue at the edges of excised breast tissue, thereby enabling surgeons to immediately resect additional tissues.  In clinical studies as an adjunct to standard of care, it has been shown to improve a surgeon's ability to achieve a complete resection of the disease, leading to lower rates of re-excision procedures.  The MarginProbe System is commercially available in Europe.  It is an investigational device in the United States.

About Dune Medical Devices

Dune Medical Devices is a private medical device company developing applications for the real time detection of cancerous tissues during surgical, interventional, and diagnostic procedures.  As a stand-alone platform or in combination with imaging modalities, Dune's breakthrough technology will provide physicians with information that has the potential to improve procedure success rates, better outcomes, and lower costs. Founded in 2002 by Dr. Dan Hashimshony and financed by Apax Partners, the Company has offices in the U.S., Europe, and Israel.  For more information, please visit www.dunemedical.com.


'/>"/>
SOURCE Dune Medical Devices, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaNet and Anapharm Europe Formally End Joint Venture
2. Paul Meade Accepts Invitation to Speak at AACE Annual Meeting
3. FDA Accepts Investigational New Drug Application for ARI-3030MO; First in Man Clinical Trial to Begin During First Quarter of 2011
4. NYSE Amex Accepts China Shenghuos Compliance Plan for Continued Listing
5. The European Medicines Agency Validates and Accepts Cell Therapeutics Marketing Authorization Application for Pixuvri™
6. The SCOOTER Store Accepts Medicare Contracts
7. FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review
8. FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection
9. FDA Accepts Sanofi Pasteurs Application to Expand Indication of Menactra® Vaccine to Infants and Toddlers
10. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
11. FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dec. 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... company focused on delivering scientific and medical breakthroughs ... Chairman and Chief Executive Officer Keith Murphy ... Wednesday, December 14, 2016 at 1:00 p.m. Eastern ... not yet familiar with the Company, an informational ...
(Date:12/7/2016)... , December 7, 2016 ... reach a value of USD 3.9 billion by ... View Research, Inc. The growth of the market ... and continuous technological advancements by the market players. ... due to increasing donation, rising awareness about transfusion-transmitted ...
(Date:12/6/2016)... 2016 Diabetes & Obesity Drug Development Pipeline ... disease cluster is currently dominated by therapeutics indicated for ... mellitus (T2DM), and the majority of the pipeline, in ... attributable to these indications. While products indicated for obesity ... are a large number of these products in the ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... “The Road To Restoration”: an informative and ... one hour a week showing of hands. “The Road To Restoration” is the creation ... are familiar with the brass ring that you could reach out for, and grab, ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Walking With God: Inspirational Lessons from My Life's ... reader to be aware of God's direction in their lives. “Walking With God: Inspirational ... teacher and active church leader. , Sanford says, “I enjoy sharing the ...
(Date:12/7/2016)... 3, 2016) , ... (PRWEB) December 07, 2016 ... ... patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, was awarded a ... Mexico with a patient engagement program. New Mexico has more people with cavernous ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... present at the International Probiotic Association’s Washington DC workshop on November 2nd. The ... engage in dialog regarding probiotic dietary supplement regulations. , Dr. Leyer spoke ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Hacking into my medical record ... him as 'a genius.'" Thus begins "Margaret in Berlin," Book Twelve in the ... Wyston Books, Inc. These novels narrate the lives of a poor teenager ...
Breaking Medicine News(10 mins):